• 한국산학기술학회논문지
• /
• 제12권3호
• /
• pp.1270-1277
• /
• 2011

제약산업은 연구개발 비중이 높은 지식기반산업으로 우수한 연구개발 인력에 기초한 연구 역량이 국가경쟁력의 핵심요소로 작용한다. 연구개발 역량이 우수한 국가가 세계시장을 선도하고, 높은 기술력만 있으면 세계 시장지배를 통해 고도성장이 가능한 분야다. 특히 제약분야의 연구개발 역량 강화를 위해서는 적정 규모의 연구인력 확보가 선결되어야할 과제다. 본 연구는 전문가 델파이 기법을 이용하여 제약분야의 연구개발 인력 수급 현황(2007년)과 함께 미래(2017년)의 인력수급 현황에 대해서 조사 분석하였다. 본 연구의 결과를 정리하면 다음과 같다. 첫째, 2007년 현재 제약 산업 분야의 연구개발 인력은 적정규모에 비해 약 5,600명 부족한 것으로 평가된다(부족률: 약 18.1%). 둘째, 향후 2017년에는 필요 연구개발 인력 대비 공급이 약 13,500명 부족할 것으로 전망되어 연구인력 수급 불균형은 향후 더 심화될 것으로 전망된다. 본 연구결과는 정부의 제약 분야에 대한 R&D 인력수급 정책의 변화가 없을 경우 향후 인력 수급에 심각한 차질(부족 현상)이 예상됨을 보여주는 만큼 합리적이고 체계적인 연구인력 수급 정책마련이 시급하게 필요함을 시사해 주고 있다.

• 보건의료산업학회지
• /
• 제9권3호
• /
• pp.247-254
• /
• 2015

Objectives : The aim of this study was to analyze the influence of foreign and institutional investors in the pharmaceutical industry on R&D investments. Methods : The empirical analysis was done for the years 2009 to 2013 which examined the period after the influence of the financial crisis. Financial statements and comments in general and internal transactions were extracted from the TS-2000 of the Korea Listed Company Association. STATA 12.0 was used as the statistical package for the panel analysis. Results : The results show that the shareholding ratio of foreigner investors turned out to have a statistically significant influence on R&D investment. No statistical significance was found in the shareholding ratio of institutional investors. Conclusions : The findings of this study, which indicate that a higher shareholding ratio of foreigner investors leads to greater R&D investment, indicate that foreign investors directly or indirectly impose pressure on a manager to make R&D investments for the long-term.

• 한국경영과학회지
• /
• 제42권3호
• /
• pp.35-49
• /
• 2017

The main objective of this paper is to empirically analyze the efficiency effects of mergers on Korean pharmaceutical firms and suggests managerial or policy implications for managers or policy makers. This study selects non-merging control firms close to the size of merging firms, as well as a set of merging firms, and measures the effects of mergers on efficiency three years before and after the merger using the non-parametric data envelopment analysis (DEA) method. To compare the differences of efficiency means among several groups, Wilcoxon rank sum test or Wilcoxon signed rank test is used. It showed that the long-term effects after the merger appeared partially. Furthermore, it was observed that there was no difference statistically in the efficiency between merging and non-merging firms. Also, there was no difference statistically in the efficiency between the pre- and post-merger periods. In conclusion, there was not any observed synergy effect through group (or affiliated) mergers between affiliates or related mergers for Korean pharmaceutical firms.

• Journal of Pharmaceutical Investigation
• /
• 제39권4호
• /
• pp.299-307
• /
• 2009

Data exclusivity is one of the most important intellectual property rights of pharmaceuticals. During data exclusivity period, third parties are prohibited from relying on the data which the original company has submitted to regulatory authority for drug application. I investigated data exclusivity systems for pharmaceuticals in the US, EU, Canada and Korea. New chemical entities were usually given the longest periods of data exclusivity compared to drugs with new indication or new formulation, although the protection periods varied by country. For new drugs to be entitled to a data exclusivity, strict conditions should be met. Data exclusivity has also been provided as an incentive to promote clinical investigation and drug development for pediatric population or orphan diseases. In Korea, data exclusivity was adopted in 1995 as an additive provision to "drug re-examination" which is to investigate post-marketing safety information of new drugs. It was introduced with few discussion on the purposes or effects of data exclusivity on pharmaceutical industry and pharmaceutical market in this country. I found that Korea's data exclusivity system falls short of considerations on valuing innovation of pharmaceutical research. It is necessary to improve data exclusivity system in order to promote innovative pharmaceutical development and to balance intellectual property rights protection and access to drugs in this country.

• 한국병원경영학회지
• /
• 제5권1호
• /
• pp.24-39
• /
• 2000

This paper aims to analyze the effects that marketing mix variables have on the marketing performance of pharmaceutical manufacturers. It examines how product characteristics, price, marketing channel and promotion effort influence the sales and market share of anti-ulcer drugs in the markets for clinics and hospitals separately. Empirical results from 29 products of anti-ulcer drugs show that sales in hospitals are affected by the profit per prescription to the physician, brand name drugs relative to generics, and the age of ingredients since its introduction to the markets. Profit per prescription to the hospital, relative price, age of ingredients and promotion effort have positive effects on the market share.

• 약학회지
• /
• 제18권4호
• /
• pp.236-242
• /
• 1974

Extrusion-spheronization processing combination was used to produce spherical granules with experimental formulations which contain microcrystalline cellulose as a diluent. The produced granules were compared on the basis of the following physical properties ; (a) bulk density, (e) porosity, (f) friabillity and (g) dissolution rate. With the specific experimental formulations used in this study, the increased plate rotational speeds of Marumerizer (400-1200rpm) produced continually more spherical material and also the obtained data indicated that the particle size distribution and dissolution rate depend upon the amount of microcrystalline cellulose used. As a result, the spherical granule preparation with microcrystalline cellulose has good properties in flow rate, packing propertyu and friability and offers a suitable method of granule preparation in pharmaceutical industry.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2001년도 Proceedings of International Convention of the Pharmaceutical Society of Korea
• /
• pp.193.2-194
• /
• 2001

• Asian Journal of Business Environment
• /
• 제12권4호
• /
• pp.35-44
• /
• 2022

Purpose: The main purpose of this study is to find out the impact of ownership structure on firm performance in the pharmaceutical and chemical industry of Bangladesh. Research design, data and methodology: The study has been conducted on 28 listed pharmaceutical and chemical companies from 2012 to 2020. Return on Assets (ROA) and Tobin's Q are selected as indicators of internal and market performance of the firms respectively whereas institutional ownership, directors' ownership and foreign ownership are selected as proxies of ownership structure. Panel analysis using random effects, lag method and time dummy method is used to analyse the relationship. Results: The study has found the existence of highly concentrated directors' ownership, a low percentage of institutional ownership and a very insignificant proportion of foreign ownership in the industry. The regression results show that directors' ownership has a positive and significant impact on firm performance, supporting the concept of agency theory. The study has also found a positive and significant impact of foreign ownership on firm performance. Unfortunately, the impact of institutional ownership is found to be insignificant. Conclusions: Directors' ownership and foreign ownership decreases agency cost that ultimately increases firm performance. However, the role of institutional investors is not significant enough to improve firm performance. It is suggested that institutional investors should be more active and involved in monitoring the activities of the organisations to improve performance.

• Asian Journal of Business Environment
• /
• 제9권2호
• /
• pp.35-46
• /
• 2019

Purpose - The purpose of this study is to find out the intellectual capital disclosure (ICD) and its determinants in the pharmaceutical and chemical industry of Bangladesh. Research design, data, and methodology - This research study is conducted on the listed firms of pharmaceutical and chemical industry in Bangladesh during the period of 2016 to 2017. This study develops a self-structured intellectual capital disclosure index; and the proxies of determinants of ICD are used as board characteristics (board size, independent directors and female directors), ownership structures (institutional ownership and director ownership), and firm characteristics (firm size, leverage and performance). The study uses a content analysis to analyze the extent of ICD and a pooled cross-sectional method to find the determinants of ICD. Research Findings - This study finds that intellectual capital disclosure is positively associated with firm size, leverage, and firm performance and negatively associated with director ownership and institutional ownership. This study also finds that there is no significant association of ICD with independent director or female director. Conclusions - The study recommends that the regulatory authority should develop mandatory guidelines on ICD for ensuring proper and consistent disclosure about the intellectual capitals. Besides, the companies should include a separate section in the annual reports to disclose the measurement and management of intellectual capital.

• 품질경영학회지
• /
• 제40권3호
• /
• pp.372-380
• /
• 2012

Purpose: The purpose of this research is to develop the methods for evaluating the business value of a company's technical portfolios. In this study, technical portfolios of 10 major manufacturers and e-Biz industries are examined first from a business model perspective. Subsequently, we suggest future direction of R&D for the pharmaceutical industry by deducing the leading industries sharing similar traits with the pharmaceutical industry. Methods: In order to evaluate and analyze the patents of the major leading industries based on the constituents of a business model, the target patents were selected through the following procedure. Results: First, In this study, using the data obtained from the patent analysis, the differences in the technology portfolios of specific business entities based on the constituents of their business models. Second, deduced business rules of particular business entities through classification analysis and role-model of pharmaceutical industry Conclusion: If enterprise discovers technological change and characters of other enterprise or technology, enterprise could judge a direction of technology which will be developed in the near term and a plan which utilized existing technology to increase enterprise's profits.